ArticleScientific reports2026
Integrative analysis of single-cell and transcriptomic data with RT-qPCR validation explores TRPM4-associated gene signatures in osteoarthritis synovium.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Osteoarthritis (OA) is a chronic, disabling condition whose pathogenesis remains unclear. TRPM4 is closely associated with OA, but its specific roles and regulatory networks within different cell subsets remain to be elucidated. This study integrates single-cell and transcriptomic sequencing data to systematically analyse the cell-specific expression patterns, key downstream molecules, and regulatory networks of TRPM4, with the aim of identifying new therapeutic targets for OA. OA-related datasets were obtained from public databases. Key cells were identified at the single-cell level, and analyses including enriched pathways and cell communication were conducted. Candidate genes were screened by cross-referencing differentially expressed genes (DEGs), key module genes from high-dimensional weighted gene co-expression network analysis (hdWGCNA) analysis related to key cells, and TRPM4-related DEGs. We then employed machine learning algorithms and expression levels to screen key genes. Subsequently, analyses such as functional enrichment, immune infiltration analysis, construction of molecular regulatory networks, and reverse transcription quantitative polymerase chain reaction (RT-qPCR) were executed. Human Leukocyte Antigen-DR Alpha Chain (HLA-DRA) cells were the key cells, and the enriched pathways they participated in mainly included "FMO oxidizes nucleophiles", and frequent cell-cell interactions were observed between HLA-DRA cells and synovial subintimal fibroblasts (SSF) in OA. Later, 2 key genes (FOSL2 and S100A11) were obtained. S100A11 was up-regulated, while FOSL2 was down-regulated in the OA group, and RT-qPCR showed consistent results (p < 0.05). In addition, FOSL2 and S100A11 shared 14 enriched pathways, such as the p53 pathway and oxidative phosphorylation, and there were infiltration differences of 8 types of immune cells between OA and control samples (p < 0.05). The miRNA-mRNA network (e.g., has-miR-6134-S100A11) was constructed. This study suggested that TRPM4-associated HLA-DRA
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.